Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data

被引：0
|
作者：
Ash Bullement
Samuel Thomas McMordie
Anthony James Hatswell
Nanxin Li
Koo Wilson
机构：
[1] Delta Hat,
[2] University College London,undefined
[3] Bioverativ,undefined
[4] a Sanofi Company,undefined
[5] Swedish Orphan Biovitrum AB (publ),undefined
来源：
PharmacoEconomics - Open | 2020年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：133 / 142
页数：9
相关论文
共 50 条
  • [21] Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects
    Katragadda, Suresh
    Neelakantan, Srividya
    Diao, Lei
    Wong, Nancy
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (07): : 889 - 900
  • [22] Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world data
    Farahbakhshian, Sepehr
    Fan, Qi
    Schultz, Bob G.
    Princic, Nicole
    Park, Julie
    Bullano, Michael
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1278 - 1286
  • [23] FINAL DATA FROM THE PREVENT STUDY EVALUATING REAL-WORLD USAGE AND EFFECTIVENESS OF A RECOMBINANT FACTOR VIII FC AND RECOMBINANT FACTOR IX FC IN HAEMOPHILIA A OR B IN GERMANY
    Bidlingmaier, C.
    Heller, C.
    Langer, F.
    Miesbach, W.
    Schotz, U.
    Oldenburg, J.
    Roehss, J.
    Falk, A.
    Santagostino, E.
    Tiede, A.
    HAEMOPHILIA, 2023, 29 : 48 - 49
  • [24] Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study
    Oldenburg, Johannes
    Hay, Charles R. M.
    Jimenez-Yuste, Victor
    Peyvandi, Flora
    Schved, Jean-Francois
    Szamosi, Johan
    Winding, Bent
    Lethagen, Stefan
    BMJ OPEN, 2019, 9 (05):
  • [25] Safety and efficacy of recombinant factor VIII FC fusion protein (RFVIIIFC) for the prevention and treatment of bleeding in previously-treated adult and adolescent subjects with hemophilia A: interim analysis of the aspire study
    Jackson, S.
    Perry, D.
    Quon, D.
    Chowdary, P.
    Shapiro, A.
    Pabinger, I
    Santagostino, E.
    Li, X.
    Glazebrook, D., V
    Allen, G. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 346 - 347
  • [26] Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia a
    Wang, Michael
    Pasi, K. John
    Pabinger, Ingrid
    Kerlin, Bryce A.
    Kulkarni, Roshni
    Nolan, Beatrice
    Liesner, Raina
    Brown, Simon A.
    Hanabusa, Hideji
    Tsao, Elisa
    Winding, Bent
    Lethagen, Stefan
    Jain, Nisha
    BLOOD, 2016, 128 (22)
  • [27] Analysis of Target Joint Bleeding with Prophylactic Use of Recombinant Factor IX Fc Fusion Protein in Patients with Severe Hemophilia B
    Shapiro, Amy D.
    Perry, David J.
    Baker, Ross I.
    Tsao, Elisa
    Mei, Baisong
    BLOOD, 2015, 126 (23)
  • [28] Real-world usage and effectiveness of recombinant factor VIII/ factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany
    Bidlingmaier, Christoph
    Heller, Christine
    Langer, Florian
    Miesbach, Wolfgang
    Scholz, Ute
    Oldenburg, Johannes
    Nueesch, Eveline
    Palmborg, Helena
    Santagostino, Elena
    Tiede, Andreas
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (05)
  • [29] HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES IN PEOPLE WITH HEMOPHILIA A (PWHA) FROM THE A-LONG/ASPIRE STUDIES OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC)
    Cockerham, A.
    DasMahapatra, P.
    Tang, W.
    Sajeev, G.
    Yang, H.
    von mackensen, S.
    HAEMOPHILIA, 2022, 28 : 58 - 58
  • [30] POSTIVE IMPACT OF SWITCHING PREVIOUSLY TREATED PATIENTS (PTPS) TO | RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) IN THE ANNUALIZED BLEEDING RATE (ABR): REAL WORLD EXPERIENCE
    Benitez Hidalgo, O.
    Martinez Garcia, M. F.
    Suito Alcantara, M.
    Castano Pantoja, J. M.
    Fernandez Sarmiento, C.
    Juarez Gimenez, J. C.
    HAEMOPHILIA, 2021, 27 : 108 - 108
12345